192753-30-3

Upstream product

• 143305-35-5 2-allyloxycarbonylamino-succinic acid 4-tert-butyl ester 
• 143305-32-2 (S)-3-allyloxycarbonylamino-4-hydroxy-butyric acid tert-butyl ester 
• 100-51-6 benzyl alcohol 
• 143305-33-3 2-allyloxycarbonylamino-4-oxobutyric acid 4-tert-butyl ester 

Downstream Products

• 821800-06-0 3(S)-acetylamino-N-{1-[((3S)-2-benzyloxy-5-oxo-tetrahydrofuran-3-ylcarbamoyl)methyl]-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl}succinamic acid benzyl ester 
• 821800-05-9 {1-[((3S)-2-benzyloxy-5-oxo-tetrahydrofuran-3-ylcarbamoyl)methyl]-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl}carbamic acid tert-butyl ester 
• 195071-91-1 N-{1-[((S)-2-Benzyloxy-5-oxo-tetrahydro-furan-3-ylcarbamoyl)-methyl]-2-oxo-6-phenethyl-1,2-dihydro-pyridin-3-yl}-3-phenyl-propionamide 
• 195071-90-0 N-{6-Benzyl-1-[((S)-2-benzyloxy-5-oxo-tetrahydro-furan-3-ylcarbamoyl)-methyl]-2-oxo-1,2-dihydro-pyridin-3-yl}-3-phenyl-propionamide 
• 195071-94-4 N-{1-[((S)-2-Benzyloxy-5-oxo-tetrahydro-furan-3-ylcarbamoyl)-methyl]-2-oxo-6-phenyl-1,2-dihydro-pyridin-3-yl}-3-phenyl-propionamide 
• 195071-92-2 N-{1-[((S)-2-Benzyloxy-5-oxo-tetrahydro-furan-3-ylcarbamoyl)-methyl]-6-butyl-2-oxo-1,2-dihydro-pyridin-3-yl}-3-phenyl-propionamide 
• 195071-89-7 (S)-N-((S)-2-Benzyloxy-5-oxo-tetrahydro-furan-3-yl)-2-[2-oxo-3-(3-phenyl-propionylamino)-2H-pyridin-1-yl]-propionamide 
• 195071-93-3 N-{1-[((S)-2-Benzyloxy-5-oxo-tetrahydro-furan-3-ylcarbamoyl)-methyl]-6-methyl-2-oxo-1,2-dihydro-pyridin-3-yl}-3-phenyl-propionamide 
• 195071-95-5 N-{1-[((S)-2-Benzyloxy-5-oxo-tetrahydro-furan-3-ylcarbamoyl)-methyl]-2-oxo-1,2-dihydro-pyridin-3-yl}-3-phenyl-propionamide 

Relevant academic research and scientific papers

Inhibitors of interleukin-1beta converting enzyme

The present invention relates to novel classes of compounds which are inhibitors of interleukin-1β converting enzyme. The ICE inhibitors of this invention are characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting ICE activity and consequently, may be advantageously used as agents against IL-1-, apoptosis-, IGIF-, and IFN-γ-mediated diseases, inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, degenerative diseases, and necrotic diseases. This invention also relates to methods for inhibiting ICE activity, for treating interleukin-1-, apoptosis-, IGIF- and IFN-γ-mediated diseases and decreasing IGIF and IFN-γ production using the compounds and compositions of this invention. This invention also relates to methods for preparing N-acylamino compounds.

Design and synthesis of a potent and selective peptidomimetic inhibitor of caspase-3

In this paper we report the synthesis and characterization of a novel potent and selective inhibitor of caspase-3, a member of the caspase family of cysteine proteases which plays an important role in many human disorders. This molecule represents 3(S)-acetylamino-N-{1-[(((3S)-2-hydroxy-5-oxo- tetrahydrofuran-3-yl)carbamoyl)methyl]-2-oxo-5-phenyl-2,3-dihydro-1H/-benzo[e] [1,4]diazepin-3-yl}succinamic acid, a monocyclic conformationally constrained form of the tetrapeptide Ac-DEVD-H, in which a 1,4-benzodiazepine nucleus is introduced internally to the peptidic sequence.

Inhibitors of interleukin-1β Converting enzyme inhibitors

The present invention relates to pyradazino[1,2-a][1,2]diazepine-1-carboxamide compounds of formula: which compounds are inhibitors of interleukin-1beta converting enzyme.